08/11/19 -"Given the favourable development in FX, FY19 revenue guidance was increased by DKK300m. As operating expenses are likely to remain stable, the operating profit target also gets an uplift by a similar ..."
Pages
48
Language
English
Published on
08/11/19
You may also be interested by these reports :
17/09/25
The massive collapse in Novo Nordisk’s share price over the last 15 months, due to competitive concerns, pricing pressure and a few other factors, ...
25/08/25
Attractive return potential remains – Confidence slightly raised
22/08/25
Though missing expectations, Novonesis demonstrated strong momentum in H1 2025, achieving 9% organic growth and 8% in Q2, resulting in a narrowed ...
21/08/25
Guidance reaffirmed while FX and destocking mask momentum